Cardio3 BioSciences’ Stem Cell Heart Therapy Phase III Trials Bolstered By New Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
Belgian biotech Cardio3 BioSciences is in a leading position in the race to develop a stem cell-based therapy for severe heart failure.
You may also be interested in...
Belgium’s Cardio3, China’s Medisun Join Hands On Phase III Trials In U.S.
Belgium’s Cardio3 BioSciences secures 25 million euros from China’s Medisun International to aid clinical trial efforts in the United States on a heart failure treatment candidate.
Mesoblast Advances Stem-Cell Drugs As Catalysts Approach
Australian regenerative medicines company Mesoblast is working with its partner Teva to move a stem-cell treatment for congestive heart failure into Phase III clinical studies.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.